Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Diabetes & Metabolic Disorders
Published in: Journal of Diabetes & Metabolic Disorders 2/2020

01-12-2020 | Glimepiride | Research article

Investigation of the synergistic effect of glimepiride and rosuvastatin on alloxan-induced diabetic rat

Authors: Debashish Mondol, Md. Nahinul Islam, Sonchita Biswas, Protic Jodder, Samiron Sana, Md. Abu Saleh, Md. Rafiqul Islam

Published in: Journal of Diabetes & Metabolic Disorders | Issue 2/2020

Login to get access

Abstract

Purpose

Diabetes mellitus is characterized by having a multitude of life-threatening secondary complications, particularly dyslipidemia, which ultimately leads to the development of comorbid diseases, such as cardiovascular diseases. This research work was designed to investigate the synergistic effect of glimepiride (1 mg/kg b.w.) and rosuvastatin (10 mg /kg b.w.) on alloxan-induced diabetic rats having dyslipidemia.

Methods

Diabetes was induced by injecting alloxan (120 mg/kg b.w.) intraperitoneally. The experiment was conducted to determine the level of blood glucose, HbA1c, lipid profile, and body weight variation of rats.

Results

This study’s outcomes suggested that the combination therapy showed more statistically significant effect on blood glucose level, HbA1c level, lipid profile, and body weight variation than any single therapy. While the glimepiride monotherapy showed a statistically considerable effect on blood glucose level, HbA1c level, and body weight variation, the rosuvastatin treated group gave statistically non-significant effect on these parameters except body weight variation, which was found as downward trend. In addition, the rosuvastatin treated group showed a healthy lipid profile compared to glimepiride treated group.

Conclusions

Concluding the results of this study, it can be said that the treatment of glimepiride in combination with rosuvastatin may be more efficacious than monotherapy for preventing diabetes in rats with dyslipidemia.
Literature
1.
Kennedy MSN, Masharani U. Pancreatic Hormones & Antidiabetic Drugs. In: Katzung BG, editor. Basic Clin Pharmacol a LANGE Med B. 14th ed. McGraw-Hill Education; 2018. p. 747–771.
2.
Philipson LH, Steiner DF. Pas de deux or more: The sulfonylurea receptor and K+ channels. Science. 1995;268:372–3.
3.
Massi-Benedetti M. Glimepiride in type 2 diabetes mellitus: A review of the worldwide therapeutic experience. Clin Ther. 2003;25:799–816.
4.
Jeng C-Y, Hollenbeck CB, Wu MS, Foley JE, Chen Y-DI, Reaven GM. Changes in carbohydrate metabolism in association with glipizide treatment of type 2 diabetes. Diabet Med. 1991;8:32–9.CrossRef
5.
Kolterman OG, Gray RS, Shapiro G, Scarlett JA, Griffin J, Olefsky JM. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Diabetes. 1984;33:346–54.CrossRef
6.
Feldman JM, Lebovitz HE, Lebovitz L. Endocrine and metabolic effects of Glybenclamide: evidence for an Extrapancreatic mechanism of action. Diabetes. 1971;20:745–55.CrossRef
7.
Briscoe VJ, Griffith ML, Davis SN. The role of glimepiride in the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2010;6:225–35. 
8.
Matafome P, Louro T, Rodrigues L, Crisóstomo J, Nunes E, Amaral C, et al. Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. Diabetes Metab Res Rev. 2011;27:54–62.CrossRef
9.
Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of rho-kinase in the pathogenesis of hypertension in humans. Hypertension. 2001;38:1307–10.CrossRef
10.
Briscoe VJ, Griffith ML, Davis SN. The role of glimepiride in the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2010;6:225–35. 
11.
Caro JJ, Ward AJ, O’Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care. 2002;25:476–81.CrossRef
12.
Toh SA, Rader DJ. Dyslipidemia in insulin resistance: Clinical challenges and adipocentric therapeutic frontiers. Expert Rev Cardiovasc Ther. 2008;6:1007–22. 
13.
Taskinen MR. Diabetic dyslipidaemia: From basic research to clinical practice. Diabetologia. 2003;46:733–49.
14.
Nii D, Tagoe A, Amo-Kodieh P. Type 2 diabetes mellitus influences lipid profile of diabetic patients. Sch Res Libr Ann Biol Res. 2013;4:88–92.
15.
Syvänne M, Taskinen MR. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet. 1997;350:20–3.CrossRef
16.
Ikeoka D, Krusinova E. Insulin resistance and lipid metabolism. Rev Assoc Med Bras. 2009;55:234.CrossRef
17.
Watts GF, Karpe F. Triglycerides and atherogenic dyslipidaemia: Extending treatment beyond statins in the high-risk cardiovascular patient. Heart. 2011;97:350–6. 
18.
Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5:150–9.
19.
Mahboob A, Taqweem A, Alam I, Ahmad I, Ali Z, Bilal M. Effect of pioglitazone on lipid profile in type 2 diabetic patients. J Postgrad Med Inst. 2013;27:13–9.
20.
Lamb RE, Goldstein BJ. Modulating an oxidative-inflammatory cascade: Potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function. Int J Clin Pract. 2008;62:1087–95.
21.
Pieroni A, Nebel S, Quave C, Münz H, Heinrich M. Ethnopharmacology of liakra: traditional weedy vegetables of the Arbëreshë of the vulture area in southern Italy. J Ethnopharmacol. 2002;81:165–85.CrossRef
22.
McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl. 2003;4:9–14. 
23.
Deedwania PC, Hunninghake DB, Bays HE, Jones PH, Cain VA, Blasetto JW. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol. 2005;95:360–6.CrossRef
24.
Ooi EMM, Nestelmd PJ, Watts GF, Sviridov D, Chan DC, Barrett PHR, et al. Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome. Diabetes Care. 2008;31:1656–61.CrossRef
25.
Bayrasheva VK, Babenko AY, Dobronravov VA, Dmitriev Y V., Chefu SG, Pchelin IY, et al. Uninephrectomized High-Fat-Fed Nicotinamide-Streptozotocin-Induced Diabetic Rats: A Model for the Investigation of Diabetic Nephropathy in Type 2 Diabetes. J Diab Res. 2016;2016:1–18. 
26.
Iams SG, Wexler BC. Alloxan diabetes in spontaneously hypertensive rats: gravimetric, metabolic and histopathological alterations. Br J Exp Pathol. 1977;58:177–99.PubMedPubMedCentral
27.
Xiong G, P. Murali D. Combination drug therapy for Alzheimer’s disease. Geriatrics. 2005;60:22–6. 
28.
Orloff DG. Fixed combination drugs for cardiovascular disease risk reduction: Regulatory approach. Am J Cardiol. 2005;96:28–33. 
29.
Kalra S, Kalra B, Agrawal N. Combination therapy in hypertension: An update. Diabetol Metab Syndr. 2010;2:44. 
30.
Sever PS, Messerli FH. Hypertension management 2011: Optimal combination therapy. Eur Heart J. Oxford Academic; 2011;32:2499–506.
31.
Miersch S, Sliskovic I, Raturi A, Mutus B. Antioxidant and antiplatelet effects of rosuvastatin in a hamster model of prediabetes. Free Radic Biol Med. 2007;42:270–9.CrossRef
32.
Piconi L, Corgnali M, Da Ros R, Assaloni R, Piliego T, Ceriello A. The protective effect of rosuvastatin in human umbilical endothelial cells exposed to constant or intermittent high glucose. J Diabetes Complicat. 2008;22:38–45.CrossRef
33.
Kaneto H, Kajimoto Y, Miyagawa J, Matsuoka T, Fujitani Y, Umayahara Y, et al. Beneficial effects of antioxidants in diabetes: possible protection of pancreatic β-cells against glucose toxicity. Diabetes. American Diabetes Association Inc. 1999;48:2398–406.
34.
Balasubramanian R, Varadharajan S, Kathale A, Nagraj LM, Periyandavar I, Nayak UP, et al. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10mg+ metformin SR 500mg in diabetic dyslipidaemia in adult Indian patients. J Indian Med Assoc. 2008;106:464–7.PubMed
35.
Abedulla Khan K, Satyanarayana S, Eswar Kumar K, Anupama K. Pharmacodynamic drug interaction of mexiletine with metformin in rats. Res J Pharm Biol Chem Sci. 2012;3:905–11.
36.
Draeger KE, Wernicke-Panten K, Lomp HJ, Schüler E, Roßkamp R. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent climepiride (Amaryl®): A double-blind comparison with clibenclamide. Horm Metab Res. Georg Thieme Verlag; 1996;28:419–25.
37.
Sonnenberg GE, Garg DC, Weidler DJ, Dixon RM, Jaber LA, Bowen AJ, et al. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus. Ann Pharmacother. New York: SAGE Publications Inc.; 1997;31:671–676.
38.
Draeger E. Clinical profile of glimepiride. Diabetes Res Clin Pract. 1995;28:S139–46.CrossRef
39.
Weitgasser R, Lechleitner M, Luger A, Klingler A. Effects of glimepiride on HbA1c and body weight in type 2 diabetes: results of a 1.5-year follow-up study. Diabetes Res Clin Pract. 2003;61:13–9.CrossRef
40.
Tsutamoto T, Yamaji M, Kawahara C, Nishiyama K, Fujii M, Yamamoto T, et al. Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with non-ischaemic chronic heart failure. Eur J Heart Fail. 2009;11:1195–201.CrossRef
41.
Jenkins DJA, Thompson AL, Wolever TMS, Vuksan V, Rao A V., Thompson LU, et al. Effect of reduced rate of carbohydrate absorption on carbohydrate and lipid metabolism. Eur J Clin Nutr. 1995;49:S68-73.
42.
Islam MS, Alam AHMK, Rahman MAA, Ali Y, Mamun A, Rahman M, et al. Effects of combination of Antidiabetic agent and statin on Alloxan-induced diabetes with cardiovascular diseases in rats. J Sci Res. 2012;4:709–20.CrossRef
43.
Md TI SN. Beneficiary Effect of Combination Therapy of Metformin and Pitavastatin Drug on Alloxan Induced Diabetic Rats Comparing to Single Drug Therapy. Clin Exp Pharmacol. 2016;06:2161–1459.
44.
Chehade JM, Mooradian AD. A rational approach to drug therapy of type 2 diabetes mellitus. Drugs. 2000;60:95–113. 
45.
Babu V, Gangadevi T, Subramoniam A. Anti-hyperglycaemic activity of Cassia kleinii leaf extract in glucose fed normal rats and alloxan-induced diabetic rats. Indian J Pharmacol. 2002;34:409–15.
46.
Balasubramanian R, Varadharajan S, Kathale A, Nagraj LM, Periyandavar I, Nayak UP, et al. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10mg+ metformin SR 500mg in diabetic dyslipidaemia in adult Indian patients. J Indian Med Assoc. 2008;106:464–7.PubMed
47.
Oyedepo TA. Effect of Citrus maxima (Merr.) fruit juice in alloxan-induced diabetic wistar rats. Sci J Med Clin Trial. 2012;2012:3–8.
48.
Brewer HB. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol Excerpta Medica. 2003;92:23–9.CrossRef
49.
Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann. Pharmacother. New York: SAGE Publications; 1998. p. 1044–52.
50.
Olfert ED, Cross BM, McWilliam AA. Guide to the care and use of experimental animals. Can Counc Anim Care. 1993;49:49.
Metadata
Title
Investigation of the synergistic effect of glimepiride and rosuvastatin on alloxan-induced diabetic rat
Authors
Debashish Mondol
Md. Nahinul Islam
Sonchita Biswas
Protic Jodder
Samiron Sana
Md. Abu Saleh
Md. Rafiqul Islam
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 2/2020
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-020-00662-6

Other articles of this Issue 2/2020

Journal of Diabetes & Metabolic Disorders 2/2020 Go to the issue

Research article

Effects of insulin treatment on hepatic CYP1A1 and CYP2E1 activities and lipid peroxidation levels in streptozotocin-induced diabetic rats

Research article

Gene set enrichment analysis of α-amylase and α-glucosidase inhibitors of Cassia glauca

Research article

Intervention of Ayurvedic drug Tinospora cordifolia attenuates the metabolic alterations in hypertriglyceridemia: a pilot clinical trial

Research article

The effects of two iso-volume endurance training protocols on mitochondrial dysfunction in type 2 diabetic male mice

Research article

Prevalence and associated factors of painful diabetic peripheral neuropathy among diabetic patients on follow up at Jimma University Medical Center

Research article

Swimming training attenuates pancreatic apoptosis through miR-34a/Sirtu in1/P53 Axis in high-fat diet and Streptozotocin-induced Type-2 diabetic rats
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits